OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
IKA$37.0060

Ilika PLC

Electrical Components & EquipmentVerified

Ilika operates with a highly leveraged capital structure, as evidenced by a price-to-book ratio of 389.46 and a price-to-tangible-book ratio of 389.46, indicating significant intangible asset valuation. The company maintains a strong liquidity position with a current ratio of 6.24 and cash and equivalents of £6.42 million, but it is experiencing negative operating cash flow of £4.18 million and free cash flow of £6.22 million, reflecting ongoing operational challenges. Profitability metrics are negative, with a return on equity of -34.36% and a return on assets of -30.35%, far below the industry norms for Electrical Components & Equipment. The company reported a net loss of £5.90 million and an operating loss of £7.56 million, indicating a need for significant cost management or revenue growth to turn around its financial performance. Geographically, Ilika's revenue is concentrated in the United Kingdom, with no disclosed international revenue segments. The Stereax product line targets medical and industrial IoT markets, while Goliath is aimed at EVs and cordless appliances. However, the company has not disclosed segment-specific revenue figures, making it difficult to assess the contribution of each product line to overall performance. Looking ahead, Ilika is projected to face continued financial pressure, with no clear path to profitability in the near term. The company's revenue of £1.05 million is modest, and there are no disclosed growth drivers or expansion plans that would suggest a significant increase in revenue in the next fiscal year. The absence of positive revenue growth and the high price-to-revenue ratio of 6348.98 further underscore the speculative nature of the investment. Risk factors include the company's negative net income and operating income, which could lead to increased financial leverage or the need for additional capital. The risk assessment indicates low liquidity and dilution risk, but the company's negative cash flows and high price-to-book ratio suggest a high valuation risk. There are no immediate filing-based liquidity or dilution flags, but the company's reliance on intangible assets and lack of profitability pose long-term risks. Recent events include the disclosure of a mean price target of £130.00 from analysts, indicating strong buy sentiment despite the company's current financial performance. The company has not issued any recent filings or transcripts that would suggest significant operational or strategic changes, and there are no disclosed events that would impact its financial outlook in the near term.

30-day price · IKA+10.96 (+42.6%)
Low$24.00High$41.00Close$36.70As of10 May, 00:00 UTC
Profile
CompanyIlika PLC
TickerIKA.L
SectorIndustrials
BusinessIndustrial Goods
Industry groupIndustrial Goods
IndustryElectrical Components & Equipment
AI analysis

Business. Ilika PLC develops solid-state battery technology for medical devices, industrial IoT, EVs, and consumer electronics, offering Stereax miniature batteries and Goliath large-format batteries.

Classification. Ilika is classified in the Industrials sector under Industrial Goods, specifically in the Electrical Components & Equipment industry with 0.92 confidence.

Ilika operates with a highly leveraged capital structure, as evidenced by a price-to-book ratio of 389.46 and a price-to-tangible-book ratio of 389.46, indicating significant intangible asset valuation. The company maintains a strong liquidity position with a current ratio of 6.24 and cash and equivalents of £6.42 million, but it is experiencing negative operating cash flow of £4.18 million and free cash flow of £6.22 million, reflecting ongoing operational challenges. Profitability metrics are negative, with a return on equity of -34.36% and a return on assets of -30.35%, far below the industry norms for Electrical Components & Equipment. The company reported a net loss of £5.90 million and an operating loss of £7.56 million, indicating a need for significant cost management or revenue growth to turn around its financial performance. Geographically, Ilika's revenue is concentrated in the United Kingdom, with no disclosed international revenue segments. The Stereax product line targets medical and industrial IoT markets, while Goliath is aimed at EVs and cordless appliances. However, the company has not disclosed segment-specific revenue figures, making it difficult to assess the contribution of each product line to overall performance. Looking ahead, Ilika is projected to face continued financial pressure, with no clear path to profitability in the near term. The company's revenue of £1.05 million is modest, and there are no disclosed growth drivers or expansion plans that would suggest a significant increase in revenue in the next fiscal year. The absence of positive revenue growth and the high price-to-revenue ratio of 6348.98 further underscore the speculative nature of the investment. Risk factors include the company's negative net income and operating income, which could lead to increased financial leverage or the need for additional capital. The risk assessment indicates low liquidity and dilution risk, but the company's negative cash flows and high price-to-book ratio suggest a high valuation risk. There are no immediate filing-based liquidity or dilution flags, but the company's reliance on intangible assets and lack of profitability pose long-term risks. Recent events include the disclosure of a mean price target of £130.00 from analysts, indicating strong buy sentiment despite the company's current financial performance. The company has not issued any recent filings or transcripts that would suggest significant operational or strategic changes, and there are no disclosed events that would impact its financial outlook in the near term.
Key takeaways
  • Ilika operates with a high price-to-book ratio of 389.46, indicating a speculative valuation.
  • The company reported a net loss of £5.90 million and an operating loss of £7.56 million, highlighting financial challenges.
  • Ilika's revenue is concentrated in the United Kingdom with no disclosed international segments.
  • Analysts have assigned a mean price target of £130.00, suggesting strong buy sentiment despite current financial performance.
  • The company's negative cash flows and high valuation risk indicate a high-risk investment profile.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyGBP
Revenue$1.1M
Gross profit$526.7k
Operating income-$7.6M
Net income-$5.9M
R&D
SG&A
D&A
SBC
Operating cash flow-$4.2M
CapEx-$2.1M
Free cash flow-$6.2M
Total assets$19.4M
Total liabilities$2.3M
Total equity$17.2M
Cash & equivalents$6.4M
Long-term debt$470.7k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$37.00
Market cap$6.69B
Enterprise value$6.68B
P/E
Reported non-GAAP P/E
EV/Revenue6349.0
EV/Op income
EV/OCF
P/B389.5
P/Tangible book389.5
Tangible book$17.2M
Net cash$6.0M
Current ratio6.2
Debt/Equity0.0
ROA-30.3%
ROE-34.4%
Cash conversion71.0%
CapEx/Revenue-2.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Industrial Goods · cohort 13 companies
MetricIKAActivity
Op margin-718.1%9.4% medp25 9.4% · p75 9.4%bottom quartile
Net margin-560.6%5.8% medp25 5.8% · p75 5.8%bottom quartile
Gross margin50.0%26.9% medp25 26.9% · p75 26.9%top quartile
R&D / revenue2.0% medp25 1.6% · p75 3.0%
CapEx / revenue-200.0%2.4% medp25 1.6% · p75 3.3%bottom quartile
Debt / equity3.0%106.4% medp25 106.4% · p75 106.4%bottom quartile
Observations
IR observations
Mean price target130.00 GBP
Median price target130.00 GBP
High price target130.00 GBP
Low price target130.00 GBP
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.04 GBP
Last actual EPS-0.04 GBP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:09 UTC#516179fc
Market quoteclose GBP 37.00 · shares 0.18B diluted
no public URL
2026-05-10 06:09 UTC#1e8176d2
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 06:11 UTCJob: 5faa7cc8